NCI and CDC to Collaborate on Gathering Cancer Statistics

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 5
Volume 9
Issue 5

BETHESDA, Md-Officials of the National Cancer Institute (NCI) and the Centers for Disease Control and Prevention (CDC) have signed a formal agreement to develop what NCI calls “a comprehensive, federally integrated cancer surveillance and cancer control research system.” The two agencies will pool and jointly release their data on cancer incidence and mortality, as well as coordinate various aspects of cancer registry management, including training and methodology development.

BETHESDA, Md—Officials of the National Cancer Institute (NCI) and the Centers for Disease Control and Prevention (CDC) have signed a formal agreement to develop what NCI calls “a comprehensive, federally integrated cancer surveillance and cancer control research system.” The two agencies will pool and jointly release their data on cancer incidence and mortality, as well as coordinate various aspects of cancer registry management, including training and methodology development.

Both agencies will also continue to expand and strengthen their separate cancer registry operations: NCI’s Surveillance, Epidemiology, and End Results (SEER) program now includes five states and five metropolitan areas, 10 rural counties in Georgia, and selected groups of Native Americans and Alaska natives. The CDC supports cancer registries in 45 states, the District of Columbia, and three US territories.

Recent Videos
Genetic consultation and next-generation sequencing can also complement treatment strategies for patients with pancreatic cancer.
Brett L. Ecker, MD, focused on the use of de-escalation therapy, which is gaining momentum in neuroendocrine tumors.
Immunotherapy options like CAR T-cell therapy and antigen-presenting cell-directed agents are currently being evaluated in the pancreatic cancer field.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Pancreatic cancer is projected to become the second-leading cause of cancer-related deaths by 2030 in the United States.
2 experts are featured in this video
2 experts are featured in this video
2 experts are featured in this video
4 KOLs are featured in this series.
Related Content